 |
|
|
|
 |
|
|
| Article 1 to 6 out of 6 concerning OSI Pharmaceuticals, Inc.
|
-
Abbott to Collaborate With Genentech, Roche and OSI on Molecular Test for Lung Cancer Therapy Response
(11 Mar 2008)
Abbott's FISH Technology Provides Analytical Tool with Potential to Assess Clinical Response to Lung Cancer Treatment in Patients with Non-Small-Cell Lung Cancer
Abbott announced that its molecular diagnostics business has entered into an agreement with Genentech, Inc., F. Hoffmann-La Roche Ltd. and OSI Pharmaceuticals, Inc. to develop a gene test to potentially assess the clinical benefit of Tarceva(R) ...
-
Dako enters new collaboration on targeted therapies for non-small cell lung cancer
(22 Aug 2007)
Dako has entered into collaboration with Genentech, OSI and Roche for the clinical development and application for a Premarket Approval Supplement (sPMA) and CE marking of EGFR pharmDx for use of the EGFR pharmDx test as a potential aid in the ...
-
OSI Pharmaceuticals: Roche Has Received Negative CHMP Opinion in European Union on Tarceva(R) in Pancreatic Cancer
(01 Aug 2006)
OSI Pharmaceuticals, Inc. announced that Roche, its international partner for Tarceva(R) (erlotinib), received a negative opinion from the European Committee for Medicinal Products for Human Use (CHMP), regarding approval of Tarceva in combination ...
-
OSI Pharmaceuticals Announces Submission of New Drug Application for Tarceva(R) in Japan
(19 Apr 2006)
OSI Pharmaceuticals, Inc. announced that a New Drug Application has been submitted in Japan covering the use of its flagship product, Tarceva(R) (erlotinib), for the treatment of advanced or recurrent non-small cell lung cancer (NSCLC). The ...
-
OSI Pharmaceuticals and Eyetech Pharmaceuticals Announce Signing of Definitive Merger Agreement
(23 Aug 2005)
OSI Pharmaceuticals, Inc. and Eyetech Pharmaceuticals, Inc. announced that they have entered into a definitive merger agreement whereby OSI has agreed to acquire Eyetech, a biopharmaceutical company that focuses on the development and ...
-
OSI Pharmaceuticals Announces Acquisition of All Minority Interest Shares of Prosidion Limited
(20 Apr 2005)
OSI Pharmaceuticals, Inc. announced that it has completed a stock-for-stock exchange resulting in the acquisition of all minority interest shares of the Company's majority-owned UK-based diabetes and obesity subsidiary, Prosidion Limited. A total of ...
|
|
|
|
|
Top
